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Protein tyrosine phosphatase (PTPase) dephosphorylation and protein tyrosine kinase (PTKs) phosphorylation of key signal
transduction proteins may be regulated by extracellular signals, making PTPases important in the regulation of cell proliferation.
Leucocyte common antigen (LAR), a receptor-like PTPase, consists of E-subunit, containing the cell adhesion molecule-like receptor
region, and P-subunit specific for a short segment of the extracellular region, the transmembrane peptide, and two cytoplasmic
PTPase domains. We produced a monoclonal antibody against the LAR P-subunit for immunohistochemical screening of LAR
expression in normal and tumourous tissues. Gliomas and gastric, colorectal, lung, breast and prostate cancers showed weak and
relatively infrequent expression. Intense and diffuse expression, however, was detected in 95% (227 out of 239) of thyroid
carcinomas, but only 12% (22 out of 128) of adenomas and no cases of benign thyroid disease were immunopositive. In contrast to
broad staining in carcinomas, LAR expression in thyroid adenomas was often found in small focal or locally invasive areas. Western
blot analysis similarly detected LAR P-subunit protein in thyroid carcinomas, but not in normal tissues. We believe this to be the first
demonstration of LAR overexpression in thyroid carcinoma and may help to elucidate the role of PTPases in the development of
malignancy.
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Protein tyrosine phosphatases (PTPases) are important regulators
in the reversible tyrosine phosphorylation of cellular protein via
their interactions with protein tyrosine kinases (PTKs). Many
oncogenes encode PTKs that participate in a large set of cellular
events, such as migration, proliferation, differentiation and
transformation, by regulating tyrosine phosphorylation of cellular
proteins (Chernoff, 1999). The observation that PTPase can
counteract PTK has led to the hypothesis that certain PTP genes
might behave as tumour suppressor genes (Hunter, 1989). The fact
that expression of certain PTPases is upregulated in hepatoma cells
and in breast and glial tumours lends weight to the hypothesis and
has identified some specific PTPases as candidates that might
influence oncogenic transformation and tumour growth (Zhai et al,
1993; Wiener et al, 1994; Elson and Leder, 1995; Li et al, 1996;
Norman et al, 1998).
To date, PTPases are structurally divided into intracellular
PTPases and transmembrane receptor-like PTPases (Walton and
Dixon, 1993; Neel and Tonks, 1997). Although intracellular
PTPases possess only one PTPase domain, receptor-like PTPases
have two cytoplasmic PTPase domains repeated in tandem. Among
the receptor-like PTPases, leucocyte common antigen (LAR)
consists of two noncovalently bound subunits, the extracellular
(E) subunit and the phosphatase (P) subunit. The 150-kDa E-
subunit is composed of three Ig domains and eight Fn III domains,
whereas the 85-kDa P-subunit has a short extracellular domain, a
transmembrane domain and two tandemly repeated PTPase
domains, 1 and 2 (Streuli et al, 1992, 1998; Tsujikawa et al,
2001). Previous investigations suggest that domain 2 is structurally
very similar to domain 1 and that its function may be to regulate
the catalytic activity or specificity of domain 1 (Krueger et al, 1990;
Streuli et al, 1990; Wang and Pallen, 1991; Nam et al, 1999). LAR
has been reported to play a regulatory role in insulin signalling via
the extracellular and two PTPase domains of the P-subunit
(Hashimoto et al, 1992; Zhang et al, 1994; Serra et al, 1995;
Tsujikawa et al, 2001). Analysis of LAR mutant proteins suggests
that domain 1 is responsible for insulin receptor dephosphoryla-
tion, while domain 2 functions in recognition of the phosphory-
lated insulin receptor.
Although increased expression of LAR has been reported in
breast cancer and in pheochromocytoma (Yang et al, 1999, 2000),
the antibody used in these studies was raised against the E-subunit,
rather than the P-subunit. To address the possibility that the LAR
P-subunit might exert PTP-influencing oncogenic activity, we
immunohistochemically screened the distribution of the P-subunit
in both normal tissues and in various human tumours, subse-
quently concentrating on a large series of thyroid tumours in
which overexpression of LAR P-subunit apparently distinguished
malignant from benign disease.
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yMATERIALS AND METHODS
Tissue specimens
All normal tissues examined were obtained from three autopsy
cases. Tumour samples were obtained from surgery cases and
included 13 gliomas, 10 meningiomas, 21 thyroid carcinomas, 16
gastric cancers, 26 colorectal cancers, 20 lung cancers, 20 breast
cancers, eight hepatocellular carcinomas, 21 renal cell carcinomas
and 32 prostate cancers. No chemotherapy was instituted before
tumour excision. We also obtained additional thyroid tumours and
samples of benign thyroid diseases obtained from surgical cases,
which included 211 papillary carcinomas, 28 follicular carcinomas,
two anaplastic carcinomas, two medullary carcinomas, 128
follicular adenomas, five nodular goiters, seven specimens from
patients suffering from Basedow’s disease (diffuse toxic goiters)
and six cases of Hashimoto’s thyroiditis. Tissue specimens were
fixed in 10% neutral-buffered formalin and embedded in paraffin,
and contiguous sections cut at 4mm for H&E staining and
immunohistochemical analyses. Additional portions of thyroid
tumours and samples of benign disease were frozen at  801C for
later Western blot analysis.
Preparation of anti-LAR P-subunit monoclonal antibody
Glutathione-S-transferase-LAR fusion protein (GST–LAR) was
employed as an immunogen. Escherichia coli AD202 was
transformed with the pGEX-2T expression vector (Amersham
Bioscience Corp., Piscataway, NJ, USA), which was incorporated to
its BamHI/EcoRI site with cDNA corresponding to 607 amino acids
spanning from the end of the transmembrane region of the LAR
P-subunit (amino-acid residues 1275–1881) through the entire
cytoplasmic region. BALB/c mice were immunised four times at
approximately 2-week intervals with 50mg of the fusion proteins.
At 4 days after the last immunisation, splenocytes from mice with
elevated antibody titres were fused with cells from the BALB/c-
derived myeloma cell stain NS1 and the resulting hybridomas were
cloned using the ClonaCell
TM-HY Hybridoma Cloning Kit
(StemCell Technologies, Inc., Vancouver, Canada). We used ELISA
to screen the culture supernatant of the cloned hybridoma using
the recombinant GST–LAR cytoplasmic domain fusion proteins.
The specificity of the anti-LAR P-subunit monoclonal antibody,
which we designated YU1, was further confirmed by Western
blotting on cell lysates from LAR-transfected COS-7 cells
(Tsujikawa et al, 2001).
Immunoblotting
Three representative frozen samples were divided into cancerous
area and the corresponding normal tissue as positive and negative
controls. The 300mg of proteins obtained from cell lysates of
frozen samples were transferred from SDS–polyacrylamide
gels to nitrocellulose membranes (Schleicher & Schuell Bio
Science, Keene, NH, USA) and endogenous enzyme activity
blocked with 3% bovine serum albumin (BSA) TBS-T (20mM
Tris-HCl pH 8.0, 137mM NaCl and 0.1% Tween 20). The
membranes were then incubated with 0.2mgml
 1 of the
anti-LAR P-subunit monoclonal antibody at room temperature
for 1h, then washed three times with TBS-T. To detect anti-
body binding, the membranes were exposed to horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG (Santa Cruz Biotech,
Inc., Santa Cruz, CA, USA) diluted in TBS-T and incubated
at room temperature for 1h. After three washings in TBS-T,
bound HRP conjugates were visualised with an enhanced
chemiluminescent reagent (Wako Pure Chemical, Industries, Ltd,
Osaka, Japan).
Immunohistochemistry
Unstained formalin-fixed tissue sections were probed for antibody
reactivity using the streptavidin–biotin (SAB) method as follows:
sections were deparaffinised and endogenous peroxidase was
blocked using 0.3% hydrogen peroxidase in methanol followed by
heating for 5min in 10mmoll
 1 of sodium citrate buffer (pH 6.0)
in a pressure cooker, then rinsed with phosphate-buffered saline
(PBS) and incubated for 20min with dilute normal rabbit serum.
Sections were incubated again at room temperature for 90min
with our anti-LAR P-subunit monoclonal antibody at a concentra-
tion of 0.1mgml
 1. Tissue sections were then exposed to biotin-
labelled rabbit anti-mouse IgG for 30min, followed by the binding
reactions using a Histofine SAB-PO kit (Nichirei, Tokyo, Japan).
Copious washing with PBS between each step was essential. The
peroxidase reactions were visualised by exposure to a solution of 3,
30-diaminobenzidine tetrahydrochloride in 0.01% hydrogen per-
oxide and counterstained with haematoxylin for microscopic
evaluation. Identically treated specimens of thyroid cancer and the
normal thyroid, which were immunopositive or negative for
Western blotting, were used for the positive and negative controls.
In evaluating the immunostaining, we selected three areas
within each stained lesion and counted the number of immunor-
eactive cells in fields of at least 200 tumour cells at a magnification
of  200. The relative degree of immunostaining was recorded as
( ) when less than 20% of cells were positive, as (+) when 20–50%
of cells were positive and as (++) when over 50% of cells were
positive. Appropriate positive and negative controls were also
included and evaluated in the same manner. Statistical analyses
were carried out using Fisher’s exact test supplemented by the
Bonferroni procedure, a method that decreases the a level by
dividing a by the number of comparisons made. Results were
considered significant at Po0.05.
RESULTS
Leucocyte common antigen is synthesised as an approximately
200-kDa precursor protein that is cleaved by an endogenous
protease into two subunits, the 150-kDa E-subunit and the 85-kDa
P-subunit (Tsujikawa et al, 2001). The anti-LAR P-subunit
monoclonal antibody, designated YU1, detected 200- and 85-kDa
protein bands, which correspond precisely to the precursor protein
and its P-subunit, respectively (Figure 1).
To identify the distribution of the LAR P-subunit in normal
tissues, we screened the expression in almost all organs of the
body. Although less than 20% of cells were positive, LAR P-subunit
expression was detected in heart (three out of three), the
hepatocytes of the liver (three out of three), renal tubular
epithelium (three out of three), the exocrine cells of the pancreas
(three out of three), stomach, small and large intestine (three out
of three), the ganglia (two out of two) and in testicular tissue,
including the seminiferous tubules and Leydig’s cells (two out of
three). Normal thyroid glands were very weakly positive in two of
three cases. The only strongly positive cells were the bronchial cells
of the lung (three out of three, data not shown).
Table 1 illustrates the immunohistochemical detection of YU1
expression in various types of human tumours. All thyroid cancers
examined were positive, with the 13 cases of papillary carcinomas
showing a signal significantly stronger (Po0.001) than that seen in
any other tumour type. Although the normal gastrointestinal
mucosal glands exhibited very weak reactivity to YU1, gastric and
colorectal cancers showed a diffuse staining pattern (Figure 2A).
Two of 20 cases of lung cancer, adenocarcinomas (10%) were
focally positive for YU1 (Figure 2B). Each of the three cases of
YU1-positive breast cancer (three of 20 cases, or 15%) was
histologically invasive ductal carcinoma (Figure 2C). Only two of
32 prostate cancers (6.25%) were immunopositive; one case
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and the other was immunoreactive only in frankly invasive areas.
Owing to the striking strong immunoreactivity of the thyroid
cancers, we turned our attention to this apparently specific
expression of LAR P-subunit in thyroid lesions, examining a large
and varied series of thyroid tumours and diseases. Table 2
summarises the results of YU1 immunostaining in thyroid tissues.
As can be seen, papillary and follicular carcinomas stained more
strongly and more frequently than any other tumour type (Figure
3A and B). The limited number of anaplastic and medullary
carcinomas were negative for YU1 as were the cases of nodular
goitre, Basedow’s disease and Hashimoto’s thyroiditis. Of the 128
cases of histologically benign thyroid adenomas, only 22 (17.2%)
stained positive. Fully half of these YU1-positive adenomas
exhibited focal, as opposed to diffuse, immunoreactivity
(Figure 3C); however, the other half of these cases (11 out of 22)
showed invasive growth into the capsule, but had not spread into
vessels or lymph channels (Figure 3D).
Figure 3A also demonstrates the very weak to nonexistent
staining of normal follicular cells. The expression pattern of YU1
in papillary carcinoma was generally diffuse and intense in
Figure 1 Western blot analysis of YU1 expression in thyroid carcinoma
and in corresponding normal tissues. A weight of 300mg of each protein
was loaded on polyacrylamide gels and transferred to nitrocellulose
membrane. Leucocyte common antigen precursor and P-subunit are
shown in the left lane at 200 and 85kDa, respectively.
Table 1 Expression of LAR P-subunit (YU1) in human tumours
Immunoreactivity
Tumour
No. of
cases ( ) (+) (++)
Percentage of
positivity
Brain tumour:
Glioma 13 12 1 0 7.7
Meningioma 10 10 0 0 0
Thyroid carcinoma 21 0 8 13 100
Gastric cancer 16 12 1 0 6.3
Colorectal cancer 26 16 10 0 38.5
Lung cancer 20 18 2 0 10.0
Breast cancer 20 17 3 0 15.0
Hepatocelluar carcinoma 8 8 0 0 0
Renal cell carcinoma 21 21 0 0 0
Prostate cancer 32 30 2 0 6.3
Immunoreactivity was expressed as: ( ) o20% of cells immunopositive; (+) 20–
50% of cells immunopositive; (++) 450% of cells immunopositive.
Figure 2 Immunohistochemical expression of LAR P-subunit (YU1) in human tumours. All cases were judged as (+). ( 200) (A) colorectal cancer; (B)
poorly differentiated lung adenocarcinoma; (C) invasive ductal breast carcinoma; (D) prostate cancer, metastatic site.
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confirmed that what we saw was indeed expression of the LAR
P-subunit in thyroid papillary carcinomas and in the correspond-
ing normal tissues by Western blot analysis (Figure 1). YU1 was
strongly expressed in 41.2% of tumours (87 of 211), and
moderately positive in 54.5% of tumours (115 of 211); the
remaining 4% of tumours (nine of 211) examined demonstrated
little to no immunoreactivity. However, five of these nine
immunonegative tumours were pretreated with Plank Rychlo
solution or ethylenediamine tetraacetate (EDTA) for decalcifica-
tion, which might have affected their ability to express YU1.
However, EDTA treatment was not a factor for the three
immunonegative follicular carcinomas. Fully 89.3% of follicular
carcinomas (25 of 28) expressed YU1 to some extent, with 21% (six
of 28) demonstrating strong expression and 67.9% (19 of 28)
displaying moderate expression. Only 11% of these tumours were
negative. The frequency of YU1 expression in papillary and
follicular carcinomas was significantly different from that seen in
both anaplastic and medullary carcinomas (P¼0.017) and in
benign diseases (Po0.001). There were no significant differences
apparent between age or sex and immunohistochemical expression
of YU1 (data not shown).
DISCUSSION
In 1992, Streuli et al (1992) reported that the LAR E-subunit was
shed from the surface of HeLa cells in culture. Subsequent
investigations on LAR expression in mammalian tumours and cell
lines, therefore, involved the use of antibodies raised against the
LAR E-subunit (Li et al, 1996; Yang et al, 1999, 2000) with largely
negative results in the tissues examined. Here we show that not
only is the LAR P-subunit expressed weakly in a number of normal
and tumourous human tissues but also that protein levels are
markedly increased in thyroid carcinoma, particularly in malig-
nant papillary type cancers. The strong LAR P-subunit expression
seen in thyroid carcinoma at significantly high frequencies
contrasts with the relatively lower expression frequencies exhibited
by other types of tumours and parallels previous data on PTPase
expression in tumours (Zhai et al, 1993; Wiener et al, 1994; Elson
and Leder, 1995; Li et al, 1996; Norman et al, 1998; Yang et al,
1999, 2000). Further, our findings are consistent with theories
linking changes in PTPase expression to thyroid tumorigenesis.
It is fairly clear that two kinds of function are carried out by
PTPases acting in concert with receptor PTKs (Villa-Moruzzi et al,
1998). The first function lies in the positive regulation of signalling
pathways; PTPases bind the phosphorylated receptor or adaptor,
which then become functional towards their substrates. The Src
homology 2 (SH2) domain-containing PTP, SHP2, thus has a
positive effect on cellular signalling (Tonks and Neel, 1996).
Overexpression of PTP a is also necessary for the dephosphoryla-
tion and activation of the Src kinase (Zheng et al, 1992). Abnormal
expression of PTK genes, such as insulin-like growth factor
Figure 3 Immunohistochemical expression of the LAR P-subunit (YU1) in thyroid tumours. (A) papillary carcinoma, judged as (++), while the normal
thyroid glands were negative ( 100), (B) papillary carcinoma, metastatic to lymph node ( 100), (C) follicular adenoma showing focally positive
immunostaining, judged as (+) because positive tumour cells were 20–50% in the lesion ( 100), (D) follicular adenoma showing strong positive staining in
invasive areas (diagnosed as invasive adenoma) ( 40).
Table 2 Expression of LAR P-subunit (YU1) in thyroid tumours and
diseases
Immunoreactivity
Thyroid tumour
No. of
cases ( ) (+) (++)
Percentage of
positivity
Papillary carcinoma 211 9 115 87 95.7
Follicular carcinoma 28 3 19 6 89.3
Anaplastic carcinoma 2 2 0 0 0
Medullary carcinoma 2 2 0 0 0
Follicular adenoma 128 106 21 1 17.2
Nodular goiter 5 5 0 0 0
Basedow’s disease 7 7 0 0 0
Hashimoto’s thyroiditis 6 6 0 0 0
Immunoreactivity was expressed as: ( ) o20% of cells immunopositive; (+) 20–
50% of cells immunopositive; (++) 450% of cells immunopositive.
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adhesion kinase (FAK), or the proto-oncogenes RET and NyK/mer,
has been shown to correlate with progression in a variety of
tumours (Luttrell et al, 1994; Liu et al, 1995; Resnik et al, 1998). A
number of tyrosine kinase genes are, in fact, expressed in thyroid,
breast and prostate cancers (Weier et al, 2001). It is possible that
our demonstrations of LAR overexpression in some other types of
tissues and tumours may be because of its role in depho-
sphorylation of receptor PTKs.
The second function of PTPases is negative signal transduction.
PTPases contribute to the return to a normal functional state by
dephosphorylating the receptor PTK; this is a major function of
the receptor-like PTPases. Overexpression of LAR downregulates
insulin-stimulated cellular responses in hepatoma cells (Li et al,
1996), suggesting that LAR acts as a physiological modulator.
Phosphorylation may also regulate tumour cell adhesion mole-
cules. Loss of these molecules has been correlated with increased
tumour invasiveness and change in phenotype (Bukholm et al,
1998). Such molecules, including p120, catenin, E-cadherin, g-
catenin (plakoglobin) and b-catenin, are apparently regulated
by tyrosine phosphorylation (Kanner et al, 1991; Hinck et al, 1994;
Xu and Carpenter, 1999). LAR expression was evidently re-
gulated by contact inhibition via E-cadherin-dependent cell–cell
communication in an in vitro study (Symons et al, 2002). Although
we could not find any correlation between LAR expression
and tumour differentiation in this study, expression may
not be because of phosphorylation mediated in this particular
fashion.
The RET gene codes for a transmembrane tyrosine kinase that
displays a cadherin-like domain and a cysteine-rich motif in the
extracellular region. Rearrangement of the RET tyrosine-kinase
receptor with different genes, especially RET/PTC1 and PTC3
generated by the fusion of RET to the H4 or RFG genes,
respectively, is frequently found in thyroid papillary carcinoma,
particularly in childhood radiation-induced thyroid cancers
(Bongarzone et al, 1994; Santoro et al, 1994; Nikiforov et al,
1997; Jhiang, 2000). A recent study demonstrated that LAR
overexpression decreased the oncogenic activity of a RET/MEN2A
mutation when LAR and RET were cotransfected with a MEN2A or
MEN2B mutation into an NIH3T3 cell line, possibly owing to
interference with RET dimerisation (Qiao et al, 2001). The
phenomenon was observed in both an in vitro colony formation
assay as well as in an in vivo tumorigenicity assay using SCID
mice. Interestingly, RET/PTC and the RET/MEN2A oncoproteins
have constitutive kinase activity consequent to ligand-independent
dimerisation (Monaco et al, 2001). We therefore suggest that LAR
overexpression may affect RET/PTC dimerisation as well as kinase
activity, and lead to reduced oncogenic potential, especially in
papillary carcinoma.
A number of diagnostic markers have been reported in thyroid
neoplasia. Recent interest has focused on the expression of
galectin-3 and thyroid transcription factor-1 (TTF-1). Studies
demonstrated the positivities of galectin-3 in 100% of papillary
carcinomas, 90–100% of follicular carcinomas, 50–80% of
medullary carcinomas, 0–33% of follicular adenomas and 0–
38% of nodular goitres (Beesley et al, 2002). Thyroid transcription
factor-1 also expressed 100% of differentiated follicular tumours
including follicular adenoma, follicular carcinoma and papillary
carcinoma, but only 25% of undifferentiated carcinoma of the
thyroid (Katoh et al, 2000). These markers were often expressed in
benign lesions as well as malignant lesions, being due to the
different mechanisms from LAR P-subunit.
We have demonstrated that overexpression of LAR P-subunit
specifically occurs in thyroid cancers, particularly in papillary and
follicular carcinomas. In addition, of the 128 thyroid follicular
adenomas examined, 22 tumours were positive for LAR P-subunit
and half of these lesions demonstrated invasive growth into the
capsule. The focal immunoreactive patterns of LAR expression in
these adenomas suggest that YU1-positive cells have malignant
potential and that adenomas expressing LAR P-subunit proteins
have a greater propensity to progress to invasive and/or metastatic
disease. Little information is available on the signal transducers
involved in RET oncogene signalling. However, an increase in LAR
may also represent a molecular mechanism for interfering with the
kinase activity of RET/PTC and reducing its oncogenic activity. If
so, monoclonal antibody YU1 against LAR P-subunit might be
useful as both a therapeutic agent as well as a tumour marker. At
the very least, it would seem to have a role in further analysis
clarifying the role of PTPases in tumorigenesis.
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